Aquestive Therapeutics, Inc. ( (AQST) ) has released its Q3 earnings. Here is a breakdown of the information Aquestive Therapeutics, Inc. presented to its investors.
Aquestive Therapeutics, Inc., a pharmaceutical company specializing in innovative drug delivery technologies, is making strides in advancing its range of orally administered and topical medicines aimed at improving patient outcomes. The firm is currently focused on developing alternative treatments for severe allergic reactions and conditions like epilepsy and alopecia areata.
In its third-quarter 2024 financial report, Aquestive highlighted several strategic developments, including the upcoming pre-NDA meeting for Anaphylm™ (epinephrine) Sublingual Film and the pre-IND meeting for AQST-108 (epinephrine) Topical Gel. Additionally, the company has expanded the market presence of Libervant® (diazepam) Buccal Film for seizure clusters in young children. Aquestive closed the quarter with approximately $78 million in cash, supporting its operations into 2026.
Financially, Aquestive reported a 4% increase in total revenues, reaching $13.5 million for the third quarter of 2024 compared to the same period in 2023. This growth was driven by license and royalty revenues, despite a decline in manufacture and supply revenue. The company’s research and development expenses rose significantly due to clinical trials, and selling, general, and administrative expenses also saw a notable increase. The net loss for the quarter widened to $11.5 million, mainly due to increased operating expenses.
Looking ahead, Aquestive’s management remains optimistic about its pipeline progress and the potential launch of Anaphylm in 2026, pending FDA approval. The company continues to focus on expanding its product offerings and market reach, while maintaining a robust cash position to support its strategic initiatives.
